AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04993534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-care DWM/PM+
Description: The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support.
Study NCT04993534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychological First Aid + usual care (CAU)
Description: All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
Study NCT06292572 — intervention group
Intervention type: PROCEDURE
Intervention: Retinal Detachment Surgery
Description: Retinal Detachment Surgery that consists in either Pars Plana Vitrectomy or Scleral Buckling or a combination of both techniques, and with or without use of intraocular tamponade
Study NCT05147064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
Study NCT05147064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional open surgery
Description: open interlaminar lumbar decompression
Study NCT06086093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RespireAid TM/placebo
Description: Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm
Study NCT06086093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: RespireAid TM/placebo
Description: Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm
Study NCT04901481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study NCT04901481 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Empower Neuromodulation System
Description: Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
Study NCT05407597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icatibant
Description: Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics.
Study NCT05407597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics.
Study NCT06368167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554
Study NCT05799599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stay-Play-Talk Basic
Description: Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
Study NCT05799599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay-Play-Talk Basic
Description: Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
Study NCT05799599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay-Play-Talk Plus
Description: SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
Study NCT05799599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stay-Play-Talk Advanced
Description: SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
Study NCT05132374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-T CHILD
Description: This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
Study NCT05900388 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
Study NCT05900388 — intervention group
Intervention type: DRUG
Intervention: Standard of care (SOC)
Description: Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
Study NCT06026748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XJ103 Injection
Description: XJ103 is a humanized monoclonal antibody.
Study NCT06026748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only excipients.
Study NCT06197334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastro-intestinal biopotentials recording
Description: Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.
Study NCT06030336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Health Report
Description: The Home Health Report has been described in the intervention arm description.
Study NCT05149664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Description: As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
Study NCT05204823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Chocolate milk shakes
Study NCT05204823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control product
Description: Glucose
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (Tec)
Description: Subcutaneous administration of Teclistamab
Study NCT06734052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPPA
Description: See CAPPA arm description.
Study NCT06734052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: See health education arm description
Study NCT04336670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality exercise program
Description: Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
Study NCT04336670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual center therapies (Physical therapy, occupational therapy..)
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous administration of Daratumumab
Study NCT05161091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical application of Orosol®
Description: Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
Study NCT05161091 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Topical application of Placebo comparator
Description: Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 1
Description: Treatment period: oral administration for 12 weeks, QD
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 2
Description: Treatment period: oral administration for 12 weeks, QD
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 3
Description: Treatment period: oral administration for 12 weeks, QD
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 4
Description: Treatment period: oral administration for 12 weeks, QD
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS5315 Dose 5
Description: Treatment period: oral administration for 12 weeks, QD
Study NCT05335499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD
Study NCT05670769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1200 mg/Kg
Description: Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100 mg/Kg
Description: Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
Study NCT05508009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: administered i.v. or orally
Study NCT05508009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
Study NCT05508009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System
Description: CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is > 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
Study NCT05508009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplant
Description: In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with > 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI >18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
Study NCT05049980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment with Mifégyne® and MisoOne®
Description: When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
Study NCT05049980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-uterine aspiration
Description: When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administration oral
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration
Study NCT05695508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Subcutaneous administration of Daratumumab
Study NCT04696965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correct/recheck strategy
Description: One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
Study NCT04696965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual verbal instruction
Description: One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
Study NCT04883827 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: 20-40 mL of blood to extract cell free DNA
Study NCT04883827 — intervention group
Intervention type: OTHER
Intervention: Urine collection
Description: up to 15 mL of urine to extract cell free DNA
Study NCT05922917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed-field ablation
Description: application of pulsed-field energy for pulmonary vein isolation and linear ablations
Study NCT05922917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed-field ablation
Description: application of pulsed-field energy for pulmonary vein isolation and linear ablations
Study NCT04546672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
Study NCT04546672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
Study NCT05102851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index
Description: Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
Study NCT06070077 — intervention group
Intervention type: PROCEDURE
Intervention: Chest compressions
Description: 2 minutes of chest compressions
Study NCT05008536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-NK Cells
Description: 1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion
Study NCT05008536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT05008536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Study NCT04791839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab will be supplied by Arcus Biosciences.
Study NCT04791839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab will be supplied by Arcus Biosciences.
Study NCT04791839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant will be supplied by Arcus Biosciences.
Study NCT05957250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Description: one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
Study NCT04666467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair
Description: Transvenous approach with a transeptal puncture to place the study device
Study NCT05503784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BITE Deodorant
Description: BITE natural Deodorant
Study NCT05833048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Participants will receive an ultrasound guided rectus sheath block with local anesthetic
Study NCT06216379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
Study NCT06461767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30
Study NCT06461767 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30
Study NCT06493344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applying additional weight
Description: Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
Study NCT06182150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Indoor Cycling Exercise
Description: The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
Study NCT06231420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Encourage using pedometer
Description: Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
Study NCT06231420 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pedometer
Description: pedometer